Immuneering Corporation (NASDAQ: IMRX) is a Healthcare company (Biotechnology) with a market capitalization of $224M. The Maz Rating grades it against the other companies in its sector.
Immuneering Corporation's current Maz Rating and its five factor grades are for members: log in to see them.
At $3.46, Immuneering Corporation trades at 1.3x book value. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -33.9%, return on invested capital of -42.9% and a free cash flow yield of -27.7%. On the balance sheet: a debt-to-equity ratio of 0.02 and a current ratio of 13.97. Over the past 52 weeks the share price ranged from $3.31 to $8.48, with a beta of 0.39.
Immuneering Corporation does not currently pay a dividend.
11 Wall Street analyst ratings cover the stock: 7 Buy and 4 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Immuneering Corporation is a biopharmaceutical company dedicated to developing novel therapeutic candidates in the fields of oncology (cancer) and neuroscience. Leading its clinical development efforts are two key drug candidates: IMM-1-104, a dual-MEK inhibitor intended for the treatment of various cancers, including pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by RAS and/or RAF gene mutations. The second is IMM-6-415, which is being developed to treat solid tumors. Beyond these advanced-stage programs, Immuneering's early-stage pipeline includes five oncology initiatives aimed at components of the MAPK or mTOR signaling pathways, along with two neuroscience programs, all currently in the discovery phase. Founded in 2008, Immuneering Corporation is headquartered in Cambridge, Massachusetts. It was formerly a subsidiary of Teva Pharmaceutical Industries Limited.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, Immuneering Corporation (IMRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.16% / 30% · (Cash+Inv) / Mkt Cap (36m) 53.2% / 30% · Interest income / Revenue 120459800.0% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 0.16% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 53.2% / 33% · Receivables / Mkt Cap (36m) 0.00% / 49% · Interest income / Revenue 120459800.0% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 0.16% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 53.2% / 33.33% · Receivables / Mkt Cap (24m) 0.00% / 33.33% · Interest income / Revenue 120459800.0% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 0.05% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 75.2% / 33.33% · Receivables / Avg Assets (4Q) 0.00% / 33.33% · Interest income / Revenue 120459800.0% / 5% | Fail |
| FTSE | Debt / Total Assets 0.24% / 33.33% · (Cash+ST Inv) / Total Assets 79.6% / 33.33% · (Cash+Recv) / Total Assets 79.6% / 33.33% · Interest income / Revenue 120459800.0% / 5% | Fail |
No. As of September 2026, Immuneering Corporation (IMRX) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. Immuneering Corporation is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 120459800.0% of each dividend: Immuneering Corporation's interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.